Marker Rescue of Adeno-Associated Virus (AAV) Capsid Mutants: a Novel Approach for Chimeric AAV Production
Open Access
- 1 January 2003
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (1) , 423-432
- https://doi.org/10.1128/jvi.77.1.423-432.2003
Abstract
Marker rescue, the restoration of gene function by replacement of a defective gene with a normal one by recombination, has been utilized to produce novel adeno-associated virus (AAV) vectors. AAV serotype 2 (AAV2) clones containing wild-type terminal repeats, an intact rep gene, and a mutated cap gene, served as the template for marker rescue. When transfected alone in 293 cells, these AAV2 mutant plasmids produced noninfectious AAV virions that could not bind heparin sulfate after infection with adenovirus dl 309 helper virus. However, the mutation in the cap gene was corrected after cotransfection with AAV serotype 3 (AAV3) capsid DNA fragments, resulting in the production of AAV2/AAV3 chimeric viruses. The cap genes from several independent marker rescue experiments were PCR amplified, cloned, and then sequenced. Sequencing results confirmed not only that homologous recombination occurred but, more importantly, that a mixed population of AAV chimeras carrying 16 to 2,200 bp throughout different regions of the type 3 cap gene were generated in a single marker rescue experiment. A 100% correlation was observed between infectivity and the ability of the chimeric virus to bind heparin sulfate. In addition, many of the AAV2/AAV3 chimeras examined exhibited differences at both the nucleotide and amino acid levels, suggesting that these chimeras may also exhibit unique infectious properties. Furthermore, AAV helper plasmids containing these chimeric cap genes were able to function in the triple transfection method to generate recombinant AAV. Together, the results suggest that DNA from other AAV serotypes can rescue AAV capsid mutants and that marker rescue may be a powerful, yet simple, technique to map, as well as develop, chimeric AAV capsids that display different serotype-specific properties.Keywords
This publication has 40 references indexed in Scilit:
- Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad SpecificityJournal of Virology, 2002
- Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface ReceptorsHuman Gene Therapy, 2001
- Enhancement of Muscle Gene Delivery with Pseudotyped Adeno-Associated Virus Type 5 Correlates with Myoblast DifferentiationJournal of Virology, 2001
- Adeno-Associated Virus Serotype 4 (AAV4) and AAV5 Both Require Sialic Acid Binding for Hemagglutination and Efficient Transduction but Differ in Sialic Acid Linkage SpecificityJournal of Virology, 2001
- Binding of Adeno-associated Virus Type 5 to 2,3-Linked Sialic Acid Is Required for Gene TransferJournal of Biological Chemistry, 2001
- Hepatic Gene Therapy Using Adeno-associated Virus VectorsSeminars in Liver Disease, 1999
- Viral vectors for gene therapyTrends in Biotechnology, 1998
- Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vectorBrain Research, 1996
- The Three-Dimensional Structure of Canine Parvovirus and Its Functional ImplicationsScience, 1991
- Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cellsCell, 1979